

Upcoming Potential Catalysts

Fig. 17: GLPG Potential Catalysts

| Time | Event | Impact | Drug | Indication | Phase | Program | NCT (or EU) # |
|------------------------------|--|--------|--------------|-------------------------------|-------|---------------|---------------|
| Filgotinib | | | | | | | |
| 1Q19 | DATA: Topline results, MTX-IR | +++ | filgotinib | Rheumatoid arthritis | 3 | FINCH 1 | NCT02889796 |
| 1Q19 | DATA: Topline results, MTX-Naive | +++ | filgotinib | Rheumatoid arthritis | 3 | FINCH 3 | NCT02886728 |
| YE18 | INITIATION (competitor): Incyte | + | baricitinib | Psoriatic arthritis | 3 | | |
| 1H19 | ENROLLMENT: complete, testicular safety study | ++ | filgotinib | ulcerative colitis | 2 | MANTA | NCT03201445 |
| 1H19 | ENROLLMENT: complete | ++ | filgotinib | ulcerative colitis | 3 | SELECTION 1 | NCT02914522 |
| 2H19 | DATA: Testicular safety Data | +++ | filgotinib | ulcerative colitis | 2 | MANTA | |
| 2H19 | ENROLLMENT: complete | ++ | filgotinib | Crohn's disease | 3 | DIVERSITY 1 | NCT02914561 |
| 2H19 | DATA (competitor): Topline bDMARD int/IR, on stable csDMARD | +++ | upadacitinib | Rheumatoid arthritis | 3 | SELECT-CHOICE | NCT03086343 |
| 2H19 | REGULATORY: FDA Filing | +++ | filgotinib | Rheumatoid arthritis | n/a | | |
| 2H19 | LAUNCH (competitor): Upadacitinib | +++ | upadacitinib | Rheumatoid arthritis | n/a | | n/a |
| 2019 | DATA (competitor): Celgene Phase 3 study results | ++ | ozanimod | Crohn's disease | 3 | | NCT03440385 |
| 2019 | DATA: Topline | ++ | filgotinib | Cutaneous lupus erythematosus | 2 | n/a | NCT03134222 |
| 2019 | DATA: Topline | ++ | filgotinib | Sjogren syndrome | 2 | n/a | NCT03100942 |
| 4Q19/1Q20 | DATA: Topline results | +++ | filgotinib | ulcerative colitis | 3 | SELECTION 1 | NCT02914522 |
| YE20 | DATA: Topline results | +++ | filgotinib | Crohn's disease | 3 | DIVERSITY 1 | NCT02914561 |
| IPF | | | | | | | |
| 4Q18 | INITIATION: Begin Dosing | ++ | 1690 | Idiopathic pulmonary fibrosis | 3 | ISABELA | NCT03711162 |
| 2H18 | INITIATION: Begin Dosing Ph 2 | + | 1205 | Idiopathic pulmonary fibrosis | 2 | n/a | n/a |
| 2H18 | INITIATION: initiate Ph 1 | + | 3499 | Idiopathic pulmonary fibrosis | 1 | n/a | n/a |
| YE19/1Q20 | ENROLLMENT: Complete | ++ | 1690 | Idiopathic pulmonary fibrosis | 3 | ISABELA | NCT03711162 |
| Atopic Dermatitis, OA | | | | | | | |
| 2H18 | INITIATION: Begin enrolling; Initiate Dosing | + | 1972 | Osteoarthritis | 2 | ROCELLA | NCT03595618 |
| 2H18 | INITIATION (competitor): AbbVie's Ph-3 trial | | upadacitinib | mod-sev atopic dermatitis | 3 | Measure Up | NCT03569293 |
| 1H19 | DATA: topline readout | +++ | MOR106 | Atopic dermatitis | 2 | IGUANA | NCT02739009 |
| 2019 | DATA (competitor): Pfizer Ph 3 topline results w/ JAK1i | | PF-04965842 | mod-sev atopic dermatitis | 3 | JADE Mono-1 | NCT03422822 |
| 2020 | DATA: Topline readout Ph2 | | 1972 | Osteoarthritis | | ROCELLA | NCT03595618 |

Source: Company reports, Instinet estimates